This inhibits the function of insulin-mediated glucose transporter 4 (GLUT4) and disrupts the downstream phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway, resulting in glucose metabolism imbalance, which further promotes the development of obesity and diabetes (Zhang et al., 2020). Here, AKT1 is linked to obesity disorder.